Elastic bioabsorbable encasements for implants.

Abstract

To provide an improved implant encasement that enables delivery of active agents to a desired site of action.SOLUTION: An elastic medical implant encasement comprises: at least one sheet of elastic material configured to form an encasement for at least part of a medical implant; and at least one biologically active substance in at least one region of the at least one sheet of elastic material.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a resilient, biocompatible absorbent article configured to accommodate a medical implant. [Background technology]

[0002] The listing or discussion of an apparently prior-published document in this specification should not necessarily be construed as an acknowledgement that the document is part of the state of the art or is common general knowledge.

[0003] Various desirable features of implants, such as antimicrobial effects and promotion of bone growth or cell recovery, are often provided to implants by the use of coatings on the implant surface. For example, bacterial colonization of the implant surface often results in infection. To combat such infections, systemic antibiotics have been used to reduce the risk of infection. However, even when a subject is treated with antibiotics systemically, infections can occur on the implant surface. Site-specific delivery of antibiotics can be an effective alternative, but metal implants are not easily modified to include a drug release mechanism for the desired period of time. With that in mind, applying a drug or antibiotic impregnated coating to the implant surface seems to be a better way to combat infection.

[0004] Thus, functional coatings, in which bioactive agents are coated on the surface of an implant, are a common way to provide implants with specific characteristics, such as antibacterial properties, bone growth properties, or cell recovery properties. However, while the use of coatings on the surface of an implant may be useful, there remain significant challenges associated with such coatings. These challenges include whether the drug being coated is suitable for such applications, the ability of the coating to adhere to the surface of the implant, and providing a controlled release of the active agent within the coating itself. Furthermore, these variations may also be affected by the active agents (e.g., analgesics, antineoplastic agents, bisphosphonates, and growth promoters) used within the coating.

[0005] Methods have been developed for coating implants, where the coat acts as a drug carrier. See, for example, Von Eiff et al., Infections Associated with Medical Devices. Drugs 2005;65(2):179-214. However, these implant coatings tend to fail, as the coatings are often too mechanically unstable to withstand the procedure of inserting and fixing the implant at the desired site in the subject. Furthermore, pre-coated implants do not allow customization of the drug or drugs delivered via the implant, as required by the specific facts surrounding the patient to be treated (e.g., the need for a specific combination of drugs).

[0006] Another practical problem with coated implants is that each coated implant is the subject of a separate approval submission and represents a new product that must go through many regulatory hurdles before it can be used in clinical practice. This is because even if the implant itself remains the same, the act of coating it with a new substance (even if it changes the active ingredient) means that regulators must validate the coating method, the coating effectiveness, the packaging and the sterilization method. As a result, if they want to offer implants with a wide choice of coatings (to address specific problems faced by patients), they need to submit each coated implant as a separate product for regulatory approval, a major undertaking. This is a major logistical and financial challenge.

[0007] One potential solution to at least some of the problems discussed above is to provide an implant encasement that contains the desired biologically active material, allowing a single implant to be placed in different encasements depending on the patient condition to be treated, allowing for easier customization.

[0008] Currently, site-specific implant encasements are limited to inelastic envelopes that hold the implant without the strict requirement to conform to the shape of the implant or for the encasement to fit within the space of the implant site. Such implants that do not have such strict requirements include pacemakers. However, many implants have stringent space and shape requirements for ergonomics and functionality, making current encasements that are loose-fitting and cannot be easily accommodated within the implant space unsuitable for use with most implants.

[0009] The current commercially available implant encasement capable of retaining antibiotics is the Medtronic Tyrx implant. Use of the Tyrx implant is largely limited to cardiovascular implantable electronic devices (CIEDs) and implantable neurosimulators (INS). The encasement provided by the Tyrx encasement is essentially in the form of an envelope or pouch. Envelope-type encasements are not suitable for implants where the entire implant must retain the implant's shape for ergonomics and functionality (e.g., hip implants). Envelope-type encasements are also not suitable for implants that are difficult to implant or have limited space requirements, such as orthopedic screws. Envelope-type encasements must be larger than the implant (so that the implant fits within it) and do not provide a grip on the implant, allowing the implant to move freely within the envelope. With this in mind, it may be necessary to enlarge the implant site slightly to accommodate the extra space and material required for the use of envelope encasements. Because such implant encasements are very flexible but not resilient, efforts have been made to make the encasements stiffer to make them easier to handle when attempting to place the implant inside the encasement. Furthermore, currently developed envelope-type implants simply coat the surface of the envelope with antimicrobial agents, which is not ideal because the drug layer is easily damaged during implantation, reducing the effectiveness of the envelope at the desired implantation site.

[0010] US Patent No. 8,900,620 describes a biocompatible sleeve that requires a closed end to ensure that the implant can be retained therein. The sleeve is made from a nonwoven sheet of absorbent polymer with a drug impregnated in the polymer. Currently, there are no commercial products that use the sleeve described in this patent. Based on the disclosed materials used in this patent, there is very little (if any) gripping force from the encasement on the implant. Otherwise, there is no need to have a second end that is closed to securely retain the medical implant. Although this patent states that the polymeric material used can be stretched (stretched) to allow the encasement to encapsulate the implant, there is no discussion of the material being elastic (and materials mentioned in the embodiment considered to be elastic) so that it can recover at least a portion of its original dimensions. Therefore, this encasement appears to have similar problems as those discussed above for envelope encasements such as the Tyrx encasement. Summary of the Invention [Problem to be solved by the invention]

[0011] Thus, there remains a need for improved implant encasements that allow delivery of active agents to the desired site of action, whether the active agents are antimicrobial in nature or other active agents such as analgesics, antineoplastic agents, bisphosphonates and growth promoters. [Means for solving the problem]

[0012] Summary of the invention Surprisingly, it has now been discovered that a resilient medical implant encasement can solve many of the problems previously disclosed herein. The resilient medical implant encasement comprises: Holding a variety of medications; be bioabsorbed; and Used in a wide range of implants; is possible.

[0013] Thus, the elastic medical implant encasement of the present invention marks an important milestone for many surgical procedures that can now include encasements where previously they were not able to do so.

[0014] Aspects and embodiments of the present disclosure are described with reference to the following numbered clauses.

[0015] 1. A resilient medical implant encasement, comprising: at least one sheet of resilient material configured to form an encasement for at least a portion of a medical implant; and at least one bioactive agent in at least one region of at least one sheet of elastic material, where the at least one sheet of elastic material is biocompatible, absorbent, and comprises at least one polymer that has 80%-100% elastic recovery after stretching or can be stretched from its original size to an expanded size and then return to its original size or to a size no greater than the expanded size minus 80% of the difference between the expanded size and the original size, and optionally, where the encasement or film can be stretched from its original size to an expanded size and then return to its original size or to a size no greater than the expanded size minus 90% of the difference between the expanded size and the original size; Encasement including.

[0016] 2. The encasement of clause 1, wherein the encasement is in the form of a tube, an envelope, a body including one or more fastening portions, a film including two or more fastening points, or a combination of any of these forms.

[0017] 3. Encasement (a) at least one sheet of elastic material having two or more fastening points formed by folding upon itself or at least one additional sheet of elastic material, the at least one sheet of elastic material carrying at least one biologically active agent in at least one region; (b) at least one sheet of elastic, biocompatible, absorbent material folded upon itself to form a single large immobilization surface, the at least one sheet of elastic material carrying at least one biologically active agent in at least one area thereof; (c) at least two sheets of elastic material sealed at overlapping areas to form one or more anchoring points or surfaces, at least one sheet of elastic material carrying at least one biologically active agent in at least one area; or (d) the encasement comprises a seamless tubular structure formed from at least one sheet of elastic material, wherein the at least one sheet of elastic material carries at least one bioactive agent in at least one region; 3. The encasement of claim 1 or 2, comprising:

[0018] 4. The encasement of any one of the preceding clauses, wherein the bioactive agent is encapsulated within and / or coated on the surface of at least one of the elastic materials.

[0019] 5. The encasement of any one of the preceding clauses, wherein the at least one sheet of elastic material is between 2 and 10 sheets of elastic material.

[0020] 6. The encasement of paragraph 5, wherein the biologically active agent is encapsulated within one or more (e.g., one) of the 2-10 sheets of elastic material and / or coated on a surface of one or more (e.g., one) of the 2-10 sheets of elastic material, and optionally, the coated surface is not an outer surface of the 2-10 sheets of elastic material.

[0021] 7. The encasement of any one of the preceding clauses, wherein the one or more elastic sheets are configured to release at least one biologically active agent at at least one release rate.

[0022] 8. The encasement of any one of the preceding clauses, wherein at least one sheet of elastic material has a total thickness of from 0.01 μm to 1000 μm.

[0023] 9. At least one polymer is selected from the group consisting of poly(lactide-co-caprolactone), poly(DL-lactide-co-caprolactone) (DL-PLCL), poly(L-lactide-co-caprolactone) (PLCL), polycaprolactone (PCL), polyglycolide (PGA), poly(L-lactic acid) (PLLA), poly(glycolide-co-caprolactone) (PGCL) copolymers, poly(D,L-lactic acid), poly(L-lactide-co-D,L-lactide) (PLDLLA), poly(L-lactide-co-caprolactone) (PGCL) copolymers, poly(D,L-lactic acid), poly(L-lactide-co-D,L-lactide) (PLDLLA), poly(L-lactide-co-caprolactone) (PGCL) copolymers, poly(D,L-lactide), poly(L-lactide-co-caprolactone) (PCL ... Poly(D,L-lactide-co-glycolide) (PLGA), poly(D,L-lactide-co-glycolide), poly(D-lactide) (PDLA), poly(trimethylene carbonate) (PTMC), poly(lactide-co-trimethylene carbonate) (PLTMC), poly(glycolide-trimethylene carbonate), polydioxanone (PDO), poly(4-hydroxybutyrate) (PHB), polyhydroxyalkanoates (PHAs), poly(phosphazenes), poly(phosphate esters), poly (amino acids), polydepsipeptides, poly(butylene succinate) (PBS), polyethylene oxide, polypropylene fumarate, polyiminocarbonate, poly(ethyl glutamate-co-glutamic acid), poly(tert-butyloxy-carbonylmethyl glutamate), poly(glycerol sebacate), tyrosine-derived polycarbonates, poly 1,3-bis-(p-carboxyphenoxy)hexane-co-sebacic acid, polyphosphazenes, ethyl glycinate polyphosphazenes, polycaprolactone-co-butyl acrylate, copolymers of polyhydroxybutyrate, copolymers of maleic anhydride, copolymers of poly(trimethylene carbonate), polyethylene glycol, hydroxypropyl methylcellulose and cellulose derivatives, polysaccharides such as hyaluronic acid, chitosan, starch, proteins such as gelatin, collagen, or PEG derivatives.

[0024] 10. The encasement of any one of the preceding clauses, wherein the number average molecular weight of the polymer is greater than 10,000 Daltons.

[0025] 11.a) at least one polymer is poly(lactide-co-caprolactone) (PLCL) (e.g., having a PLA:PCL ratio of 90:10 to 60:40) or derivatives and copolymers thereof; and / or b) at least one polymer is poly(DL-lactide-co-caprolactone) (DL-PLCL) (e.g., having a DL-PLA:PCL ratio of 90:10 to 50:50) or derivatives and copolymers thereof; and / or c) at least one polymer is poly(glycolide-co-caprolactone) (PGCL) (e.g., having a PGA:PCL ratio of 90:10 to 10:90) or derivatives and copolymers thereof; and / or d) the encasement according to any one of the preceding clauses, wherein at least one polymer is a blend of PLCL or DL-PLCL or PGCL and a releasing agent selected from one or more of the group selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or poly ethylene glycol having a molecular weight of 200 to 2000 Daltons, in a weight (wt:wt) ratio of PLCL or DL-PLCL or PGCL:releasing agent of from 25:1 to 1:9. 12. The biologically active substance is selected from the group consisting of adrenal cortex suppressants, beta-adrenergic degraders, androgens or antiandrogens, antianemics, antiparasitics, anabolic agents, anesthetics or analgesics, resuscitators, antiallergics, antiarrhythmics, antiarteriosclerotics, antibiotics, antidiabetics, antifibrinolytics, anticonvulsants, angiogenesis inhibitors, anticholinergics, enzymes, coenzymes or corresponding inhibitors, antihistamines, antihypertensives, antihypotensives, anticoagulants, antifungals, antiseptics, disinfectants, antihemorrhagic agents, beta-receptor and calcium channel antagonists, antimyasthenics, antiinflammatory agents, antipyretics, antirheumatics, antiseptics, cardiac stimulants, chemotherapeutic agents, coronary artery dilating agents, cytostatics, glucocorticoids, hemostatics, immunoglobulins or their phyla. The encasement of any one of the preceding clauses, wherein the encasement is selected from one or more of the group consisting of: fragments, chemokines, cytokines, prodrugs of cytokines, mitogens, physiological or pharmacological inhibitors of mitogens, cell differentiation factors, cytotoxic agents and their prodrugs, hormones, immunosuppressants, immunostimulants, mineralocorticoids, morphine antagonists, muscle relaxants, narcotics, vectors, peptides, (para)sympathomimetics or (para)sympatholytics, proteins, cells, selective estrogen receptor modulators (SERMs), sedatives, antispasmodics, substances that inhibit bone resorption, vasoconstrictors or vasodilators, viral growth inhibitors, and wound healing substances.

[0026] 13. The biologically active substance is an androgen or antiandrogen, an anesthetic or analgesic, an antibiotic, an antiarrhythmic, an antiarteriosclerotic, an antifibrinolytic, an angiogenesis inhibitor, an anticholinergic, an enzyme, a coenzyme or a corresponding inhibitor, an antihypertensive, an antihypotensive, an anticoagulant, an antifungal, a beta-receptor and calcium channel antagonist, an anti-inflammatory, a coronary artery dilator, a cytostatic, a glucocorticoid, a hemostatic, an immunoglobulin or a fragment thereof, a chemokine, a cytokine, a prodrug of a cytokine , mitogens, physiological or pharmacological inhibitors of mitogens, cell differentiation factors, cytotoxic agents and their prodrugs, hormones, immunosuppressants, mineralocorticoids, morphine antagonists, vectors, peptides, proteins, cells, selective estrogen receptor modulators (SERMs), sedatives, antispasmodics, substances that inhibit bone resorption, vasoconstrictors or vasodilators, viral growth inhibitors, and wound healing substances.

[0027] 14. The biologically active substance is (a) an antibacterial or antifungal agent (e.g., the antibacterial agent may be tobramycin, or more specifically, tetracycline and its derivatives (such as minocycline, tigecycline, and doxycycline), rifampin, triclosan, chlorhexidine, penicillin, aminoglycosides, quinolones, vancomycin, gentamicin, cephalosporins (e.g., cephalosporins), carbapenems, imipenems, ertapenems, antimicrobial peptides, cecropin-melittin, magainin, dermaseptin, camtamine, cephalosporins ... The antibacterial agent may be selected from one or more of the group consisting of thelicidin, alpha-defensin, alpha-protegrin and pharma- ceutical acceptable salts thereof (e.g., a combination of rifampin with another antibacterial agent, such as a combination of rifampin with a tetracycline derivative); the antibacterial agent may be selected from one or more of the group consisting of rifampin and minocycline, doxycycline, and tigecycline (e.g., rifampin and doxycycline, rifampin and tigecycline, or more specifically, rifampin and tigecycline). antifungal agents may be azoles (ketoconazole, clotrimazole, miconazole, econazole, itraconazole, fluconazole, bifoconazole, terconazole, butaconazole, ter ... ol, tioconazole, oxiconazole, sulconazole, sapeconazole, clotrimazole, voriconazole, clotrimazole, etc.), allylamines (such as terbinafine), morpholines (such as amorolfine and naftifine), griseofulvin, haloprogine, butenafine, tolnaftate, nystatin, cyclohexamide, ciclopirox, flucytosine, terbinafine, amphotericin B and pharmaceutically acceptable salts thereof); (b) antithrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyl ketone); (c) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogens, sulfasalazine, and mesalamine; (d) anesthetics such as lidocaine, bupivacaine, and ropivacaine; (e) anticoagulants such as D-Phe-Pro-Arg chloromethylketone, RGD peptide-containing compounds, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, antithrombin antibodies, antiplatelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as hyaluronic acid, growth factors (ciliary neurotrophic factor, fibroblast growth factor, hepatocyte growth factor, bone morphogenetic proteins), transcription activators and translation promoters; (g) vascular cell proliferation inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, and bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase inhibitors and tyrosine kinase inhibitors (e.g., tyrphostin, genistein, quinoxalines); (i) Cytotoxic agents, cytostatic agents and cytostatic affectors; (j) vasodilators; (k) drugs that interfere with endogenous vasoactive mechanisms; (l) inhibitors of leukocyte recruitment, such as monoclonal antibodies; (m) bone morphogenetic proteins, such as cytokines and metabologens; (n) hormone; (o) inhibitors of HSP90 proteins (i.e., heat shock proteins that are molecular chaperones or housekeeping proteins and are required for the stability and function of other client proteins / signaling proteins involved in cell proliferation and survival) such as geldanamycin; (p) alpha receptor antagonists (such as doxazosin, tamsulosin) and beta receptor agonists (such as dobutamine, salmeterol), beta receptor antagonists (such as atenolol, metaprolol, butoxamine), angiotensin II receptor antagonists (such as losartan, valsartan, irbesartan, candesartan and telmisartan), and antispasmodics (such as oxybutynin chloride, flavoxate, tolterodine, hyoscyamine sulfate, diclomine); (q) bARKct inhibitors; (r) phosphorane inhibitor; (s) the Serca2 gene / protein; and (t) immune response modifiers such as aminoquizolines, for example imidazoquinolines such as resiquimod and imiquimod; 14. The encasement of clause 13, wherein the encasement is selected from one or more of the group consisting of:

[0028] 15. At least one elastic sheet may further include holes, optionally each of the holes having a diameter of 0.1 mm to 5 mm (e.g., 0.3 mm to 2 mm), and optionally: (i) the shape of the holes is uniform and / or the holes are circular; and / or (ii) the holes are not uniform in size; and / or (iii) holes on the band are evenly distributed over the band and are concentrated in the center (avoiding the seal) or closer to the seal; 6. An encasement according to any one of the preceding clauses.

[0029] 16. The encasement of any one of the preceding clauses, wherein the encasement is selected from the group consisting of a pacemaker encasement or, more specifically, an orthopedic implant encasement, a dental implant encasement, a simulator / sensory implant encasement, a subdermal implant encasement, a monitoring implant (e.g., a biosensor chip) encasement, a breast implant encasement, an intrauterine contraceptive device encasement, an Eustachian tube (tympanostomy tube) encasement, and a tube (e.g., a catheter) encasement (wherein the encasement covers at least a portion of the implant).

[0030] 17. The encasement of clause 16, wherein at least a portion of the encasement is smaller in size than the implant to which it is to be applied and provides a gripping force when the encasement is applied to the implant.

[0031] 18. The encasement of any one of the preceding clauses, wherein at least one sheet of elastic material has an elastic recovery of 80% to 100% (e.g., 85% to 100%, 90% to 100%, or 95% to 100%) after stretching up to 300% (e.g., stretching up to 100%) and comprises at least one polymer that is biocompatible, absorbable.

[0032] 19. A method of forming a resilient medical implant encasement, comprising: (a) providing at least one sheet of elastic material in at least one region thereof, the sheet further comprising at least one bioactive agent; and (b) forming the at least one sheet into a resilient medical implant encasement; A method comprising:

[0033] 20. The method according to paragraph 19, comprising: (A) (i) providing at least one sheet of elastic material further comprising at least one bioactive agent in at least one region of the sheet; (ii) folding at least a portion of the sheet upon itself to form an edge; and (iii) sealing at least a portion of the edge to form a resilient material implant encasement; and / or (B) (i) providing at least two sheets, at least one sheet of elastic material further comprising at least one bioactive agent in at least one region of the sheet; (ii) partially overlapping at least two sheets in at least one region to form an overlap region; and (iii) sealing at least a portion of the overlap region to form a resilient material implant encasement; and / or (C) providing a seamless tubular structure of elastic material having at least one bioactive agent in at least one region; A method comprising:

[0034] 21. The method of claim 19 or 20, wherein the forming and / or sealing is accomplished using one or more methods selected from the group consisting of heat sealing, chemical sealing, and adhesives.

[0035] 22. A medical implant at least partially covered with a resilient medical implant encasement according to any one of paragraphs 1 to 18.

[0036] 23. The medical implant according to clause 22, wherein the medical implant is selected from the group consisting of a pacemaker or, more specifically, an orthopedic implant, a dental implant, a mimetic / sensory implant, a subdermal implant, a monitoring implant (e.g., a biosensor chip), a breast implant, an intrauterine contraceptive device, an ear tube (tympanostomy tube), and a tube (e.g., a catheter).

[0037] Features of the preferred embodiments will now be described with reference to the following drawings, in which like elements are similarly labeled, and in which: [Brief description of the drawings]

[0038] [Figure 1] 1 shows a schematic diagram of a top view of a bioresorbable encasement designed in accordance with an embodiment of the present invention and a medical implant in the form of a bone plate insertable within the encasement. [Diagram 2] 2A and 2B show schematic diagrams of a resilient bioabsorbable encasement according to another embodiment of the present invention, where FIG 2A shows a side view of the encasement and FIG 2B shows a bottom view of the encasement of FIG 2A. [Diagram 3] FIG. 3 is the embodiment of FIG. 2, showing a side view of a medical implant in the form of a bone plate that can be inserted into the encasement. [Figure 4] 1 is a side view of a contoured resilient bioabsorbable encasement in accordance with the principles of the present invention and a contoured medical implant in the form of a hip joint implant insertable therein; FIG. [Diagram 5] 1 is a side view of a tubular resilient bioabsorbable encasement and a non-standard medical implant in the form of an orthopedic screw insertable therein in accordance with the principles of the present invention; FIG. [Figure 6] 1 is a graph plotting force versus strain (or elongation) percentage for a representative film suitable for use in the present invention, and the elastic recovery of the film after the strain is released. [Figure 7] Figures 7-1 through 7-8 show examples of layered designs according to embodiments of the present invention. The numbering in each of Figures 7-1 through 7-8 indicates an example for the preparation of each layer. Layer 7-C (V) in Figure 7-8 refers to the use of Example 7-C to prepare a layer, but with the active agent replaced by vancomycin. [Figure 8] 1 shows the cumulative release profiles of minocycline (8-1) and rifampin (8-2) in an exemplary embodiment of the present invention. [Figure 9] 1 shows the cumulative release profile of minocycline and rifampin in a single film according to one embodiment of the present invention. [Figure 10] 1 shows the cumulative release profile of vancomycin in a single film according to one embodiment of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] explanation The present invention generally relates to elastic biocompatible encasements that serve the purpose of retaining bioactive agents for site-specific features for use with medical implants. The devices may include two or more bioactive agents and one or more layers of a biodegradable polymeric film. The polymeric film may be constructed as a single layer or a multi-layer structure. The bioactive agents may be incorporated into one, all, or some layers of the biodegradable polymeric film. The bioactive agents may be released locally into the surrounding tissue over time.

[0040] The present invention provides a surprisingly effective alternative to previously mentioned methods, such as directly coating the implant with a polymer and / or bioactive material. at least one sheet of resilient material configured to form an encasement for at least a portion of a medical implant; and at least one bioactive substance in at least one region of at least one sheet of elastic material, where the at least one sheet of elastic material comprises at least one polymer that is biocompatible and absorbent and has an elastic recovery of 80%-100% after stretching or is capable of stretching from its original size to an expanded size and then returning to its original size or a size equal to or less than the expanded size minus 80% of the difference between the expanded size and the original size; Encasement will be provided, including:

[0041] For example, the encasement or film can stretch from its original size to an expanded size and return to its original size or to a size less than or equal to the expanded size minus 90% of the difference between the expanded size and the original size.

[0042] Alternatively or additionally, the at least one sheet of elastic material has an elastic recovery of 80% to 100% (e.g., 85% to 100%, 90% to 100%, or 95% to 100%) after stretching to 300% elongation (e.g., stretching to 100%).

[0043] The encasement of the present invention is made of an elastic bioabsorbable polymer that can fit snugly around at least a portion of a medical implant. The encasement acts as a carrier for one or more biologically active agents (such as, but not limited to, antibiotics, or more specifically, growth agents) for a specific purpose. The encasement is proportionately made of an elastic material to conform to the shape and size of the portion of the implant to which it is applied, thereby fitting snugly around the portion of the implant to which it is applied. With this in mind, the implant can maintain approximately its original size, shape and function without compromising its effectiveness.

[0044] As will be appreciated, it is intended that the elastic encasement will occupy a smaller percentage of the portion of the medical implant to which it is intended to be fixed. With this in mind, when the elastic encasement is applied to the medical implant, it provides a gripping force between the elastic encasement and the medical implant, preventing the encasement from falling off or moving during normal use and implantation of the medical implant (even if the implant covered with the encasement is subjected to shear forces during implantation). Since the encasement is made of an absorbent material, the encasement will dissolve in the human or animal body after a period of time, leaving only the implant if the implant itself is not biodegradable. The elastic medical implant encasement described herein can deliver site-specific functionality with minimal deformation to the shape and method of use of the medical implant, while allowing customization of bioactive agents provided with the implant to better fit the needs of the subject undergoing treatment. The snug fit and gripping force between the article and the implant is due to the elasticity of the polymer used.

[0045] Currently available implant encasements for site-specific function lack any gripping force and therefore need to be larger than the implant to which they are applied. This causes the problems mentioned above, such as lack of space to fit the encasement to the desired implantation site, or the inability to use the encasement due to the implant moving within the encasement, resulting in inadequate coverage of the implant and causing infection. In contrast, the ability to hold the medical implant in a fixed position relative to the encasement before, during and after successful implantation is due to the gripping force generated by the elasticity of the encasement material. This elasticity allows the encasement of the present invention to be designed to have any shape or size that can hold all or part of the medical implant securely, provided that at least part of the design can mechanically generate a gripping force on the implant. This greatly expands the scope of encasement design compared to current technology. For example, currently used encasements must be provided in a form larger than the implant, which creates a space between the encasement and the implant, requiring a larger implantation site to accommodate the extra space, which is not always possible or desirable. The encasement of the present invention alleviates the need for this extra space, thereby eliminating (or at least substantially reducing) the need for enlargement of the implantation site.

[0046] The elastic encasements described herein can precisely conform to all or part of the shape and design of the implant, which is not possible with current encasements. This is highly advantageous as it allows for the retention of the ergonomic design and function of the original implant, which can be critical to its use. For example, current encasements are not suitable for use with implants where the shape affects the functionality of the implant, including, but not limited to, hip replacement implants or dental implant screws. The firm grip and ability to conform to the shape of the implant means that the encasements described herein can be used for difficult implants, such as the insertion of stem implants in hip replacements, or the insertion of screws used in dental or orthopedic implants, where the implantation procedure generates high shear or other mechanically disruptive forces and the implantation site has limited space. Thus, the present encasements further expand the potential applications of encasements in medical implants.

[0047] Without wishing to be bound by theory, the ability to conform to the shape of a medical implant may also lead to better efficiency of the applied drug. For example, if the article of the present invention is preloaded with antibiotics for anti-infection purposes, a form-fitting encasement on the surface of the implant may better prevent biofilms from forming on the surface of the implant. As another example, if the article of the present invention is preloaded with a bone bonding agent for a bone implant, a form-fitting encasement may help to better promote bone growth near the surface of the implant where the encasement is located.

[0048] The term "encasement" as used herein relates to an object that partially or entirely covers a medical device. More specifically, a part or the whole of the encasement is intended to be fixed to a part or the whole of the medical device and held in place by the gripping force provided by one or more fixed parts of the encasement. The fixed parts of the encasement provide the aforementioned gripping force by being smaller in size than the implant to which they are applied, and by being elastic. Thus, the fixed parts must expand to a size larger than the medical implant part to which they are attached in order to allow them to be fitted into place, but then the fixed parts provide a gripping force effect on the surface of the medical implant to which they are applied by elastically recovering towards their original size.

[0049] The encasement may be in any suitable form that results in at least a portion of the medical implant being covered by the encasement. Suitable forms that may be mentioned herein include, but are not limited to, a mesh, a pouch, a bag, an envelope, a sleeve, a pocket, or a receptacle, all of which may optionally include an opening, band, or design that allows the encasement to be gripped over at least a portion of the implant surface.

[0050] As used herein, "anchoring portion" can refer to the entire encasement (e.g., the elasticity of the entire pouch provides a gripping force to the surface of the implant to which it is applied, and thus the entire pouch acts as the anchoring portion), or to a portion of the encasement (e.g., an elastic loop secured to the body of the encasement).

[0051] The term "at least one elastic sheet" is intended to encompass situations where there is only one elastic sheet, or possibly more than one elastic sheet (e.g., 2-20, 3-15, 4-10, etc.). The term "sheet" as used herein is not intended to refer only to flat objects that can be folded and sealed to create more complex objects (e.g., envelopes), but is also intended to cover seamless objects, such as a tube-shaped sheet that may be integrally formed by extrusion and is also seamless. Two or more sheets can be used in combination to provide encasement, as described in more detail below.

[0052] Thus, in certain embodiments of the present invention, thin layers of elastic bioabsorbable material can be manufactured into implants of various designs to accommodate medical devices prior to implantation. The various encasement designs are to optimize uniformity of material on the implant. The article is designed to be smaller than the implant, at least in part, for elasticity to create a firm grip on the implant. A variety of drugs can be retained by the product, such as antibiotics for treating infections and osteoconductive agents for bone growth. Drugs can be retained via layered means. The article can have one or more layers of the same drug or layers of different drugs. Further discussion of drugs is provided below.

[0053] Examples of appropriate encasement forms include: (a) at least one sheet of elastic material having two or more fastening points formed by folding upon itself or at least one additional sheet of elastic material, the at least one sheet of elastic material carrying at least one biologically active agent in at least one region; (b) at least one sheet of elastic, biocompatible, absorbent material folded upon itself to form a single large immobilization surface, the at least one sheet of elastic material carrying at least one biologically active agent in at least one area thereof; (c) at least two sheets of elastic material sealed at overlapping areas to form one or more anchoring points or surfaces, at least one sheet of elastic material carrying at least one biologically active agent in at least one area; or (d) the encasement comprises a seamless tubular structure formed from at least one sheet of elastic material, wherein the at least one sheet of elastic material carries at least one bioactive agent in at least one region; These include, but are not limited to:

[0054] In the embodiments herein that may be mentioned herein, the at least one elastic material sheet may have a thickness of 0.01 μm to 1000 μm.

[0055] In the embodiments herein that may be mentioned herein, at least one elastic sheet may further comprise holes. For example, the diameter of each of the holes is 0.1 mm to 5 mm (e.g., 0.3 mm to 2 mm). For the avoidance of doubt, unless otherwise specified, the holes may be of any shape and may be uniform or irregular in shape as well as size. In particular examples that may be mentioned herein, one or more of the following may apply: (i) the shape of the holes is uniform and / or the holes are circular; and / or (ii) the holes are not uniform in size; and / or (iii) holes on the band are evenly distributed over the band and are concentrated in the center (avoiding the seal) or closer to the seal; 6. An encasement according to any one of the preceding clauses.

[0056] For example, in certain embodiments, the hole shapes may be completely uniform across the entire encasement or completely irregular. In some cases, however, an encasement may have one or more regions with uniformly shaped holes and one or more regions where the holes are irregular. Other configurations are possible within the possible combinations of the above features.

[0057] The terms "medical implant" and "implantable medical device" refer to any medical device that can be implanted percutaneously or any indwelling medical device that includes a percutaneous component. Examples of medical implants that may be mentioned herein include, but are not limited to, orthopedic implants, dental implants, mimetic / sensory implants, subcutaneous implants, monitoring implants (e.g., biosensor chips), breast implants, intrauterine contraceptive devices, Eustachian tubes (tympanostomy tubes), implantable tubes (e.g., catheters), arteriovenous shunts, left ventricular assist devices, tissue expanders, gastric lap bands, and intrathecal infusion pumps.

[0058] Examples of orthopedic implants that may be mentioned herein include, but are not limited to, hip replacements, knee replacements, shoulder replacements, elbow replacements, ankle replacements, cervical / spinal artificial discs, screws (e.g., cervical / spinal screws), pins, plates, and rods (e.g., cervical / spinal rods).

[0059] Examples of dental implants that may be mentioned herein include, but are not limited to, endosseous and subperiosteal implants (eg mandibular prostheses / plates, and dental implant abutments).

[0060] Examples of mimetic / sensory implants that may be mentioned herein include, but are not limited to, brain (or neural) implants (e.g., implantable neurostimulators (INS), deep brain stimulators), spinal cord stimulators, gastric electrical stimulators, sacral nerve stimulators, vagus nerve stimulators, and cochlear implants.

[0061] It will be understood that depending on the size and dimensions of the encasement in question, the encasement may be suitable for a single specific purpose or may be suitable for use with multiple implants. For the avoidance of doubt, the encasement may be one or more of a pacemaker encasement, or more specifically, an orthopedic implant encasement, a dental implant encasement, a simulated / sensory implant encasement, a subcutaneous implant encasement, a monitoring implant (e.g., a biosensor chip) encasement, a breast implant encasement, an intrauterine contraceptive device encasement, an ear tube (tympanostomy tube) encasement, and a tube (e.g., a catheter) encasement (wherein the encasement covers at least a portion of the implant). Other encasements may be derived by analogy with the list of medical implants provided herein. In certain embodiments of the invention, the encasement is not a CIED encasement.

[0062] As used herein, "elastic recovery" refers to the ability of all or a portion of an encasement to reversibly stretch or plastically deform in at least one direction, and preferably two directions, upon application of a force, and to recover toward its original size when the force is removed.

[0063] The encasement can stretch at least 1.1 times (e.g., 1.2 to 10 times) to allow the implant to be inserted into the encasement, and can recover 80% or more to securely hold the implant within the encasement and prevent them from separating during implantation. The structure of the encasement that may be referred to herein includes at least one film, which itself includes at least one polymer layer and at least one antimicrobial agent; and at least one opening and multiple holes in the surface.

[0064] As used herein, an elastic sheet can be stretched in any direction up to 10 times its original size (e.g., 1.1 to 4 times its original size), and then after release of the stretch, can recover to at least 80%, such as at least 90% of its original size. For example, if a film is stretched from size A to size B (difference of size C), the film will return to a maximum size B-(0.8xC) after stretching and release, where C is BA, and the maximum size is B-(0.9xC), etc. That is, if a film is stretched from 0.1 cm to 0.11 cm (difference of 0.01 cm), the resulting film will have a maximum size of 0.11-(0.8x0.01)=0.102 cm if the film recovers to at least 80%, or a maximum size of 0.101 cm if the film recovers to at least 90% of its original size after stretching. It will be understood that the film can recover to its original size or approximately its original size. Additionally or alternatively, the elastic sheet used in the present invention can have an elastic recovery of 80% to 100% after stretching to 100% of its original length. For example, when a 1×1 cm elastic sheet is stretched to a size of 2 cm in at least one direction, the sheet recovers to at least 1.2 cm (e.g., 1.2 cm to 1 cm) in the stretched direction. In certain embodiments of the invention that may be mentioned herein, the elastic recovery exhibited by one or more elastic sheets can be 85% to 100%, 90% to 100%, or 95% to 100% after stretching to 100% of its original length. It will be understood that the elasticity of the sheet depends not only on the composition of the polymeric material itself, but also on the structure imparted to the material during its processing.

[0065] In an embodiment of the invention, at least a portion of the encasement is dimensionally smaller than the implant to which it is applied and provides a gripping force when the encasement is applied to the implant, the gripping force being provided by the elastic recovery of at least one elastic sheet used in the encasement.

[0066] The terms "absorbable" or "bioabsorbable" as used herein refer to a polymeric material that can be dissolved or degraded upon contact with tissues and / or fluids within a subject's body, e.g., by enzymatic or chemical means. Absorbable polymers that may be mentioned herein include poly(lactide-co-caprolactone), poly(DL-lactide-co-caprolactone) (DL-PLCL), poly(L-lactide-co-caprolactone) (PLCL), polycaprolactone (PCL), polyglycolide (PGA), poly(L-lactic acid) (PLLA), poly(glycolide-co-caprolactone) (PGCL) copolymers, poly(D,L-lactic acid), poly(L-lactide-co-D,L-lactide) (PLDLLA), poly(L-lactide-co-glycolide) (PLGA), poly(D,L-lactide-co-glycolide), poly(D-lactide) (PDLA), poly(trimethylene carbonate) (PTMC), ), poly(lactide-co-trimethylene carbonate) (PLTMC), poly(glycolide-trimethylene carbonate), polydioxanone (PDO), poly(4-hydroxybutyrate) (PHB), polyhydroxyalkanoates (PHAs), poly(phosphazenes), poly(phosphate esters), poly(amino acids), polydepsipeptides, poly(butylene succinate) (PBS), polyethylene oxide, polypropylene fumarate, polyiminocarbonate, poly(ethyl glutamate-co-glutamic acid), poly(tert-butyloxy-carbonylmethyl glutamate), poly(glycerol sebacate), poly(1,2-dimethylamino acids), poly(methylcellulose), poly(methylcellulose), poly(ethyl cellulose), poly(1,2-dimethylamino acids ...3-Bis-(p-carboxyphenoxy)hexane-co-sebacic acid, polyphosphazene, ethyl glycinate polyphosphazene, polycaprolactone-co-butyl acrylate, copolymers of polyhydroxybutyrate, copolymers of maleic anhydride, copolymers of poly(trimethylene carbonate), polyethylene glycol (PEG), hydroxypropyl methylcellulose and cellulose derivatives, polysaccharides (such as hyaluronic acid, chitosan, starch), proteins (such as gelatin and collagen) or PEG derivatives and their copolymers (e.g., the bioabsorbable polymer of at least one polymer layer is poly(DL-lactide-co-caprolactone) (DL-PLCL), or more specifically polycaprolactone (PCL), polyglycolide (PGA), poly(L-lactic acid) (PLA), polydioxanone (PDO), poly(4-hydroxybutyrate) (PHB), polyhydoroyl ether (HYD) (POLY ... Examples of suitable polymers include, but are not limited to, polyoxyalkanoates (PHAs), PEG and its derivatives and copolymers thereof (which may be selected from one or more of the group consisting of poly(DL-lactide-co-caprolactone) (DL-PLCL), or more particularly poly(L-lactide-co-caprolactone) (PLLCL), poly(glycolide-co-caprolactone) (PGCL) copolymers, or more particularly polycaprolactone (PCL), polyglycolide (PGA), poly(L-lactic acid) (PLA), PEG and its derivatives and copolymers thereof). Specific polymers that may be mentioned include polycaprolactone (PCL), poly(DL-lactide-co-caprolactone) (DL-PLCL), poly(glycolide-co-caprolactone) (PGCL), poly(lactide-co-caprolactone) (PLCL) and its derivatives and copolymers thereof.

[0067] For example, absorbable polymers include poly(lactide-co-caprolactone), poly(DL-lactide-co-caprolactone) (DL-PLCL), poly(L-lactide-co-caprolactone) (PLCL), polycaprolactone (PCL), polyglycolide (PGA), poly(L-lactic acid) (PLLA), poly(glycolide-co-caprolactone) (PGCL) copolymers, poly(D,L-lactic acid), poly(L-lactide-co-D,L-lactide) (PLDLLA), poly( L-lactide-co-glycolide) (PLGA), poly(D,L-lactide-co-glycolide), poly(D-lactide) (PDLA), poly(trimethylene carbonate) (PTMC), poly(lactide-co-trimethylene carbonate) (PLTMC), poly(glycolide-trimethylene carbonate), polydioxanone (PDO), poly(4-hydroxybutyrate) (PHB), polyhydroxyalkanoates (PHA), poly(phosphazene), poly(phosphate esters), poly(amino acids), polydepsipeptides, poly(butylene succinate) (PBS), polyethylene oxide, polypropylene fumarate, polyiminocarbonates, poly(ethyl glutamate-co-glutamic acid), poly(tert-butyloxy-carbonylmethyl glutamate), poly(glycerol sebacate), tyrosine-derived polycarbonates, poly 1,3-bis-(p-carboxyphenoxy)hexane-co-sebacic acid, polyphosphazenes, ethyl glycinate polyphosphazenes, polycaprolactone-co-butyl acrylate, copolymers of polyhydroxybutyrate, copolymers of maleic anhydride, copolymers of poly(trimethylene carbonate), polyethylene glycol, hydroxypropyl methylcellulose and cellulose derivatives, polysaccharides such as hyaluronic acid, chitosan, starch, proteins such as gelatin and collagen or PEG derivatives and copolymers thereof.

[0068] In certain embodiments of the invention that may be mentioned herein, the elastic sheet may be made of one or more polymer sheets, each sheet may be made of: a) poly(lactide-co-caprolactone) (PLCL) (e.g., having a PLA:PCL ratio of 90:10 to 60:40) or derivatives and copolymers thereof; and / or b) poly(DL-lactide-co-caprolactone) (DL-PLCL) (e.g., having a DL-PLA:PCL ratio of 90:10 to 50:50) or derivatives and copolymers thereof; and / or c) poly(glycolide-co-caprolactone) (PGCL) (e.g., having a PGA:PCL ratio of 90:10 to 10:90) or its derivatives and copolymers thereof; and / or d) A blend of PLCL or DL-PLCL or PGCL with a releasing agent selected from one or more of the group selected from polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or poly ethylene glycol having a molecular weight of 200 to 2000 Daltons, in a weight (wt:wt) ratio of PLCL or DL-PLCL or PGCL:releasing agent of 25:1 to 1:9.

[0069] In certain embodiments of the invention that may be mentioned herein, the number average molecular weight of the polymer may be from 10,000 to 2,000,000 Daltons, preferably from 50,000 to 1,500,000.

[0070] Unless otherwise specified herein, a polymer in the form of a copolymer may be a random copolymer, an alternating copolymer having regularly alternating A and B units, a periodic copolymer in which the A and B units are arranged in a repeating sequence (e.g., (ABABBAAAABBB)n), a random copolymer, or a block copolymer, in which two or more homopolymer subunits are covalently linked. In certain embodiments of the invention, the copolymer may be a random block copolymer.

[0071] Reference herein (in any aspect or embodiment of the invention) to a "biologically active agent" and / or a "biological agent" includes reference to such agent / agent per se as well as to a pharma- ceutically acceptable salt or solvate of such agent / agent. Pharmaceutically acceptable salts that may be mentioned include acid addition salts and base addition salts. Such salts can be formed by conventional means, for example, by reacting the agent / agent in free acid or free base form with one or more equivalents of a suitable acid or base, optionally in a solvent or in a medium in which the salt is insoluble, followed by removal of said solvent or medium using standard techniques (e.g., in vacuum, by lyophilization or filtration). Salts can also be prepared by exchanging the counterion of the agent / agent in the form of a salt for another counterion, for example, using a suitable ion exchange resin.

[0072] Examples of pharma- ceutically acceptable salts include acid addition salts derived from mineral and organic acids, as well as salts derived from metals such as sodium, magnesium, or preferably potassium and calcium.

[0073] Examples of acid addition salts are acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, arylsulfonic acids (e.g., benzenesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid and p-toluenesulfonic acid), ascorbic acid (e.g., L-ascorbic acid), L-aspartic acid, benzoic acid, 4-acetamidobenzoic acid, butanoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(1S)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid (e.g., D-gluconic acid), glucuronic acid (e.g., 1,2-dihydroxyethanesulfonic acid), 1,2-dihydroxyethanesulfonic acid, ... D-glucuronic acid), glutamic acid (e.g., L-glutamic acid), α-oxoglutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, isethionic acid, lactic acid (e.g., (+)-L-lactic acid and (±)-DL-lactic acid), lactobionic acid, maleic acid, malic acid (e.g., (-)-L-malic acid), malonic acid, (±)-DL-mandelic acid, metaphosphoric acid, methanesulfonic acid, Acid addition salts include those formed with 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, L-pyroglutamic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, tartaric acid (e.g., (+)-L-tartaric acid), thiocyanic acid, undecylenic acid, and valeric acid.

[0074] Particular examples of salts are those derived from mineral acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid, sulfuric acid, and the like; from organic acids such as tartaric acid, acetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid, succinic acid, arylsulfonic acid, and the like; and from metals such as sodium, magnesium, or, preferably, potassium and calcium.

[0075] As mentioned above, the bioactive substances / biological agents described herein also include any solvates of the substances / agents and their salts.Preferred solvates are those formed by the incorporation of molecules of non-toxic pharma- ceutically acceptable solvents (hereinafter referred to as solvating solvents) into the solid structure (e.g., crystalline structure) of the compounds of the present invention. Examples of such solvents include water, alcohols (e.g., ethanol, isopropanol, and butanol) and dimethylsulfoxide.Solvates can be prepared by recrystallizing the compounds of the present invention with a solvent or a mixture of solvents, including solvating solvents.Whether or not a solvate has been formed in any given instance can be determined by subjecting the crystals of the compound to analysis using well-known standard techniques, such as thermogravimetric analysis (TGE), differential scanning calorimetry (DSC), and X-ray crystallography.

[0076] The solvates may be stoichiometric or non-stoichiometric solvates. Particularly preferred solvates are hydrates, examples of which include hemihydrates, monohydrates and dihydrates.

[0077] For a more detailed discussion of solvates and methods used to prepare and characterize them, see Bryn et al., Solid-State Chemistry of Drugs, 2nd Edition, 1999, published by SSCI, Inc., West Lafayette, Indiana, USA, ISBN 0-967-06710-3.

[0078] The bioactive substances / biological agents described herein are intended to be administered as part of the encasement when the encasement is attached to the medical implant. Thus, the bioactive substances / biological agents described herein may generally be administered as part of the encasement and / or may be coated onto a portion of a surface of the encasement (i.e., coated onto a surface of a portion of one of the at least one sheet of elastic material) and / or may be encapsulated within the at least one sheet of elastic material.

[0079] It will be appreciated that the at least one sheet of elastic material may comprise only one sheet or may comprise more than one sheet, for example, 2-10 sheets of elastic material. In embodiments of the invention in which there are two or more sheets, the bioactive agent may be encapsulated within one or more (e.g., one) of the two or more sheets of elastic material and / or coated on a surface of one or more (e.g., one) of the two or more sheets of elastic material, optionally where the coated surface is not an outer surface of the two or more sheets of elastic material (and thus effectively encapsulated between at least two sheets of elastic material). For the avoidance of doubt, each sheet of elastic material may be made from the same polymeric material as the other sheets, or each sheet may be made using a different material, or any combination between these extremes.

[0080] The bioactive substances / biological agents described herein may be provided in admixture with a pharma- ceutically acceptable adjuvant, diluent or carrier, which may be selected in consideration of the intended route of administration and standard pharmaceutical practice. Such pharma-ceutically acceptable carriers may be chemically inert to the active compounds and may have no adverse side effects or toxicity under the conditions of use. Suitable pharmaceutical formulations may be found, for example, in Remington The Science and Practice of Pharmacy, 19th Edition, Mack Printing Company, Easton, Pennsylvania (1995). A brief review of methods of drug delivery may also be found, for example, in Langer, Science (1990) 249, 1527.

[0081] Otherwise, the preparation of suitable formulations for use in the present invention may be routinely accomplished by one of ordinary skill in the art using routine techniques and / or in accordance with standard and / or accepted pharmaceutical practice.

[0082] The amount of the bioactive substance / biological agent described herein in any pharmaceutical formulation used in accordance with the present invention will depend on a variety of factors, such as the severity of the condition to be treated, the particular patient to be treated, as well as the compound being used. In any event, the amount of the compound of formula I in the formulation can be routinely determined by one of ordinary skill in the art.

[0083] For example, the implant may contain 0.001-99% (w / w) active ingredient; 0-99% (w / w) diluent or filler; 0-20% (w / w) disintegrant; 0-5% (w / w) lubricant; 0-5% (w / w) flow aid; 0-50% (w / w) granulating or binding agent; 0-5% (w / w) antioxidant; and 0-5% (w / w) pigment and 1-99.9% w / w polymeric material.

[0084] However, in the context of the present invention, the dosage administered to a mammal, particularly a human, should be sufficient to produce a therapeutic response in the mammal over a reasonable period of time. Those skilled in the art will recognize that the selection of the exact dosage and composition and the most suitable delivery schedule will also be influenced by, among other things, the pharmacological properties of the formulation, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient, as well as the effectiveness of the specific compound, the age, condition, weight, sex and response of the patient being treated, and the stage / severity of the disease. In any case, the practitioner, or other skilled in the art, can routinely determine the actual dosage that will be most appropriate for an individual patient. The dosages above are examples of the average case; of course, there can be individual cases in which higher or lower dosage ranges are justified, and such are within the scope of the present invention.

[0085] Biologically active substances / biological agents which may be mentioned herein are adrenal cortex suppressants, beta-adrenergic degraders, androgens or antiandrogens, antianemics, anthelmintics, anabolic agents, anesthetics or analgesics, central nervous system stimulants, antiallergics, antiarrhythmics, antiarteriosclerotics, antibiotics, antidiabetic agents, antifibrinolytics, anticonvulsants, angiogenesis inhibitors, anticholinergics, enzymes, coenzymes or corresponding inhibitors, antihistamines, antihypertensives, antihypotensives, anticoagulants, antifungal agents, antiseptics, antiinfectives, antihemorrhagic agents, beta-receptor and calcium channel antagonists, antimyasthenics, antiinflammatory agents, antipyretics, antirheumatics, antiseptics, cardiac stimulants, chemotherapeutic agents, coronary dilating agents, cell proliferation inhibitors. agents, glucocorticoids, hemostatic agents, immunoglobulins or fragments thereof, chemokines, cytokines, prodrugs of cytokines, mitogens, physiological or pharmacological inhibitors of mitogens, cell differentiation factors, cytotoxic agents and their prodrugs, hormones, immunosuppressants, immunostimulants, mineralocorticoids, morphine antagonists, muscle relaxants, narcotics, vectors, peptides, (para)sympathomimetics or (para)sympatholytics, proteins, cells, selective estrogen receptor modulators (SERMs), sedatives, antispasmodics, substances that inhibit bone resorption, vasoconstrictors or vasodilators, antiviral drugs, and wound healing substances. For example, the biologically active agent is selected from one or more of the group consisting of androgens or antiandrogens, anesthetics or analgesics, antibiotics, antiarrhythmics, antiarteriosclerotics, antifibrinolytics, angiogenesis inhibitors, anticholinergics, enzymes, coenzymes or corresponding inhibitors, antihypertensives, antihypotensives, anticoagulants, antifungals, beta receptor and calcium channel antagonists, anti-inflammatory agents, coronary dilators, cytostatics, glucocorticoids, hemostatics, immunoglobulins or fragments thereof, chemokines, cytokines, prodrugs of cytokines, mitogens, physiological or pharmacological inhibitors of mitogens, cell differentiation factors, cytotoxic agents and their prodrugs, hormones, immunosuppressants, mineralocorticoids, morphine antagonists, vectors, peptides, proteins, cells, selective estrogen receptor modulators (SERMs), sedatives, antispasmodics, substances that inhibit bone resorption, vasoconstrictors or vasodilators, virostatics, and wound healing substances.

[0086] In certain embodiments that may be mentioned herein, the biologically active agent is selected from the group consisting of adrenal cortex suppressants, beta adrenergic degraders, androgens or antiandrogens, antianemic agents, anesthetics or analgesics, central nervous system stimulants, antiarrhythmics, antiarteriosclerotics, antidiabetic agents, antifibrinolytic agents, antispasmodics, angiogenesis inhibitors, anticholinergics, antihypertensives, antihypotensives, anticoagulants, antifungal agents, beta receptor and calcium channel antagonists, antimyasthenic agents, antiinflammatory agents, antirheumatic agents, cardiac inotropes, coronary vasodilators, The therapeutic agent may be selected from one or more of the group consisting of cytostatics, glucocorticoids, hemostatic agents, cell differentiation factors, cytotoxic agents and their prodrugs, hormones, immunosuppressants, immunostimulants, mineralocorticoids, morphine antagonists, muscle relaxants, narcotics, (para)sympathomimetics or (para)sympatholytics, selective estrogen receptor modulators (SERMs), sedatives, antispasmodics, substances that inhibit bone resorption, vasoconstrictors or vasodilators, and wound healing substances.

[0087] As used herein, the term "analgesic" refers to any drug that provides an analgesic effect or provides blocking of nociceptive and / or neuropathic pain. Analgesics that may be mentioned herein include, but are not limited to, buprenorphine, nalbuphine, benzocaine, dyclonine hydrochloride, phenol, aspirin, phenacetin, acetaminophen, potassium nitrate, and pharma- ceutically acceptable salts thereof, and mixtures thereof.

[0088] Antineoplastic agents that may be mentioned herein include, but are not limited to, doxorubicin, vinblastine, vincristine, 5-fluorouracil (5-FU), daunorubicin, epirubicin, mitoxantrone, and cyclophosphamide, or combinations thereof.

[0089] Bisphosphonates that may be mentioned herein include, but are not limited to, etidronate, clodronate, tiludronate, neridronate, olpadronate, alendronate, ibandronate, risedronate and zoledronate, or combinations thereof.

[0090] Examples of more specific biological agents that can be used herein include, but are not limited to, the following: (a) an antibacterial or antifungal agent (e.g., the antibacterial agent may be tobramycin, or more specifically, tetracycline and its derivatives (such as minocycline, tigecycline, and doxycycline), rifampin, triclosan, chlorhexidine, penicillin, aminoglycosides, quinolones, vancomycin, gentamicin, cephalosporins (e.g., cephalosporins), carbapenems, imipenems, ertapenems, antimicrobial peptides, cecropin-melittin, magainin, dermaseptin, camtamine, cephalosporins ... The antibacterial agent may be selected from one or more of the group consisting of thelicidin, alpha-defensin, alpha-protegrin and pharma- ceutical acceptable salts thereof (e.g., a combination of rifampin with another antibacterial agent, such as a combination of rifampin with a tetracycline derivative); the antibacterial agent may be selected from one or more of the group consisting of rifampin and minocycline, doxycycline, and tigecycline (e.g., rifampin and doxycycline, rifampin and tigecycline, or more specifically, rifampin and tigecycline). antifungal agents may be azoles (ketoconazole, clotrimazole, miconazole, econazole, itraconazole, fluconazole, bifoconazole, terconazole, butaconazole, ter ... ol, tioconazole, oxiconazole, sulconazole, sapeconazole, clotrimazole, voriconazole, clotrimazole, etc.), allylamines (such as terbinafine), morpholines (such as amorolfine and naftifine), griseofulvin, haloprogine, butenafine, tolnaftate, nystatin, cyclohexamide, ciclopirox, flucytosine, terbinafine, amphotericin B and pharmaceutically acceptable salts thereof); (b) antithrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyl ketone); (c) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogens, sulfasalazine, and mesalamine; (d) anesthetics such as lidocaine, bupivacaine, and ropivacaine; (e) anticoagulants such as D-Phe-Pro-Arg chloromethylketone, RGD peptide-containing compounds, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, antithrombin antibodies, antiplatelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as hyaluronic acid, growth factors (ciliary neurotrophic factor, fibroblast growth factor, hepatocyte growth factor, bone morphogenetic proteins), transcription activators and translation promoters; (g) vascular cell proliferation inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, and bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase inhibitors and tyrosine kinase inhibitors (e.g., tyrphostin, genistein, quinoxalines); (i) Cytotoxic agents, cytostatic agents and cytostatic affectors; (j) vasodilators; (k) drugs that interfere with endogenous vasoactive mechanisms; (l) inhibitors of leukocyte recruitment, such as monoclonal antibodies; (m) bone morphogenetic proteins, such as cytokines and metabologens; (n) hormone; (o) inhibitors of HSP90 proteins (i.e., heat shock proteins that are molecular chaperones or housekeeping proteins and are required for the stability and function of other client proteins / signaling proteins involved in cell proliferation and survival) such as geldanamycin; (p) alpha receptor antagonists (such as doxazosin, tamsulosin) and beta receptor agonists (such as dobutamine, salmeterol), beta receptor antagonists (such as atenolol, metaprolol, butoxamine), angiotensin II receptor antagonists (such as losartan, valsartan, irbesartan, candesartan and telmisartan), and antispasmodics (such as oxybutynin chloride, flavoxate, tolterodine, hyoscyamine sulfate, diclomine); (q) bARKct inhibitors; (r) phosphorane inhibitor; (s) the Serca2 gene / protein; and (t) Immune response modifiers such as aminoquizolines, for example imidazoquinolines such as resiquimod and imiquimod.

[0091] In a more particular embodiment of the present invention, the biological agent used herein is selected from (a)-(g) of the list immediately above.

[0092] In some embodiments that may be mentioned herein, the bioactive substance / biological agent is not an antibiotic (e.g., the bioactive substance / biological agent is not an antibiotic and the encasement is not a CIED encasement).

[0093] Any type of drug or biological agent can be retained by the encasement, and the invention is not limited by the type used, unless otherwise specified in the embodiments of the invention described herein. It should be noted that any reference to a "drug" herein is broadly defined as any medically relevant biological agent that can be beneficially incorporated into the encasement for distribution to the implantation site of a medical implant.

[0094] As used herein, the term "peptide" includes one or more peptides, peptide derivatives, or combinations thereof. Thus, the terms "peptide", "peptides", and "derivatives of peptides" are used interchangeably throughout. "Peptide" refers to both natural and synthetic peptides, including natural or unnatural amino acids. Peptide derivatives are created by chemically modifying the side chains or free amino or carboxy termini of natural or unnatural amino acids. This chemical modification includes the addition of additional chemical moieties as well as modification of functional groups in the side chains of amino acids. Peptides are polymers having 3 to 50 amino acids, preferably more than 3, 5, 10, 15, 20, 30, 40 amino acids. The term "protein" is distinct from the term "peptide" in that it includes one or more proteins, protein derivatives, or combinations thereof, and refers to a polymer containing an amino acid chain of more than 50 amino acids.

[0095] As used herein, a "growth factor" is a chemical that regulates cellular metabolic processes, including, but not limited to, differentiation, proliferation, synthesis of various cellular products, and other metabolic activities. Growth factors can include several families of chemicals, including, but not limited to, cytokines, eicosanoids, and differentiation factors.

[0096] The present invention provides a "one size fits all" solution to the aforementioned coated implant problems. Instead of creating an inventory of many different coated implants, an encasement is instead provided that preferably includes a biological material that can fit a range of different conventional uncoated / coated implants. Thus, according to one aspect of the invention, an elastic encasement is configured to advantageously accommodate a wide variety of implant types, shapes, and sizes. In a preferred embodiment, the elastic encasement has at least a portion that is stretched to fit over the implant. The stretching will create a corresponding gripping force due to its elasticity.

[0097] According to another aspect of the invention, an encasement is implanted in a patient and an active agent is distributed from the encasement to tissue surrounding the implantation site in vivo over time. In one embodiment, the duration and dosage of agent delivered from the encasement to the patient can be controlled by factors such as the choice of encasement material used, the configuration of the encasement, and the type and form of agent impregnated in the encasement, or combination of agents and / or agent delivery systems, as further described herein. The release periods of different agents can be the same or different. The release of the agents can be timed to be independent or simultaneous.

[0098] In one embodiment, the encasement can be in the form of a pouch, envelope, or sleeve where the encasement surrounds most of the implant. This provides a large gripping area on the implant. In this aspect, the embodiment can have an encasement that is only a portion smaller than the implant, but it is more likely that the encasement will be smaller than the implant.

[0099] In another embodiment, the encasement can be designed to only partially surround the implant. This can be a film with anchoring points where the film is stretched over the implant or the anchoring points are stretched over the implant, or both. In this aspect, the embodiment can have an encasement that is smaller than the implant, but it is likely that only a portion of the encasement is smaller than the implant.

[0100] In another embodiment, the encasement can be designed to fit the shape of the implant and is not limited to regular shapes such as, for example, an envelope design for a pacemaker or an elongated design for a plate.

[0101] Another possible embodiment of the encasement generally includes at least one sheet made of a biologically compatible material and at least one bioactive agent impregnated into the encasement.

[0102] Another possible embodiment of the encasement includes multiple drugs carried by the biocompatible material. The drugs can be carried in different layers and arranged in any order or symmetrical order with respect to the biocompatible material.

[0103] The rate of distribution of the bioactive agent can be manipulated from days to months. The polymer chemistry of the polymer and the type of polymer used provide a wide range of possible drug delivery kinetics and polymer absorption times. Additionally, absorption times and drug delivery rates can be manipulated by the thickness of the sheet used to construct the polymer encasement and the addition of release agents. Other techniques can be used to control the rate and duration of delivery of drugs or biological agents. For example, in certain embodiments of the encasements and / or films of the present invention: (a) The film may have at least two polymer layers. For example, the film can have 2 to 10 polymer layers (e.g., 2 to 9 polymer layers, e.g., 3 to 7 polymer layers); (b) at least one polymer layer may further comprise a release agent consisting of one or more biocompatible hydrophilic small molecules having a hydrophobic-lipophilic balance of greater than 6 (e.g., the release agent is selected from one or more of the group consisting of sorbitol, xylitol, glycerin, mannitol, polyethylene glycol (PEG) having a number average molecular weight of 200-2000, polysorbate and urea (e.g., polysorbate 40, or more particularly, one or more of polysorbate 20, polysorbate 60 and polysorbate 80); (c) the at least one bioactive agent can be miscible with the bioabsorbable polymer of each polymer layer in which it is present; (d) in at least one layer of the polymeric film, the at least one bioactive agent may be uniformly distributed within the at least one polymeric layer in which it is present (e.g., when the at least one bioactive agent is distributed within a polymeric layer, it is homogeneously distributed within the polymeric layer); (e) when the film has at least two polymer layers, the at least one bioactive agent is distributed within the at least two polymer layers; (f) when the film has at least two polymer layers, the at least one bioactive agent is sandwiched between the two layers to form a separate layer; (g) in at least one layer of the polymer film, the at least one bioactive agent may be present in an amount of 0.1 wt% to 99 wt% of the polymer layer, such as 0.1 wt% to 95 wt% (e.g., 0.1 wt% to 90 wt% or 0.1 wt% to 80 wt%, e.g., 0.1 wt% to 60 wt%), e.g., in at least one layer of the polymer film, the at least one bioactive agent may be present in an amount of 0.1 wt% to 30 wt% of the polymer layer (e.g., 1 wt% to 25 wt%), optionally wherein the polymer layer is solvent cast and / or wherein the at least one bioactive agent is present in an amount of 10 wt% to 95 wt% of the polymer layer (e.g., 10 wt% to 60 wt%, or 30 wt% to 95 wt%, e.g., 40 wt% to 80 wt%) % by weight, optionally where the polymer layer is spray coated onto the substrate.

[0104] In one embodiment, the encasement can include a plurality of openings, which in one embodiment can be circular perforations or holes. In another embodiment, the opening shapes can be irregular and the dimensions can vary. In a preferred embodiment, the (opening area / total area) ratio can be 0%-95%.

[0105] In one embodiment, the encasement may be formed using a single sheet having a fastener formed by folding at least a portion of the sheet onto itself and sealing at least a portion of the edges to secure the fold.

[0106] In another embodiment, the encasement may be formed using multiple sheets having a fastener formed by overlapping at least two sheets that differ in at least one area and sealing at least a portion of the overlapped area.

[0107] In another embodiment, the encasement can be a single seamless tubular structure.

[0108] In another embodiment, the encasement may be a combination of a seamless tubular structure and a sheet.

[0109] So that the present invention can be understood, preferred embodiments, given by way of example only, are described herein with reference to the accompanying drawings. Preferred embodiments are therefore set forth for convenience of reference, without limiting the present invention to the embodiments described herein. The scope of the present invention is defined by the appended claims.

[0110] The invention will now be explained in more detail with reference to non-limiting embodiments and figures.

[0111] FIG. 1 shows a resilient medical implant encasement 10 disposed on a medical device such as an orthopedic implant (e.g., an elongated bone plate) 30. As shown, the encasement 10 can include a body 20 (in this case elongated) having two ends 21, 22. One of the ends 21, 22 is open and the other is open or closed, so that if at least one end is open, it allows for at least a portion of the orthopedic implant to be passed therethrough and placed therein. In one embodiment, both ends 21 and 22 are preferably open at both ends, thereby allowing the implant to be inserted into the encasement 10 from both sides. In another embodiment, one of the ends 21 or 22 is a closed end such that the implant is inserted into the encasement 10 only from the open end, thereby providing a pouch that grips the implant after insertion of the implant into the pouch / encasement 10. In the embodiment encompassed by FIG. 1, at least a portion of body 20 and / or end 21 and / or end 22 is smaller than a complementary portion of the implant such that the implant is securely held or gripped by the encasement after insertion of the implant into the end of the encasement. It will be appreciated that when the body is smaller than the implant, the gripping force may be provided by the body due to elastic deformation of the body since the body is prevented from relaxing due to fixation provided by one or more of ends 20, 21 and / or the implant. More generally, the grip provided by the end of the encasement, and potentially the remainder of the body of the encasement, results from the elasticity of the sheet used to make the encasement, stretching sufficiently to allow the implant to be inserted into the encasement, after which the sheet returns to its original size. The grip provided by the encasement prevents the implant from slipping relative to the encasement (or vice versa) when the implant is implanted or secured in the surgical site of the patient. Of course, all or a portion of the encasement 10 may contain at least one bioactive agent, as described above, along with any necessary excipients or release agents.

[0112] Figure 2A shows a side view of a further elastic encasement 11 having a bioactive agent loaded therein in accordance with the principles of the present invention, and Figure 2B shows a bottom view of the same embodiment shown in Figure 2A.

[0113] FIG. 3 shows the elastic encasement 11 of FIG. 2 with a medical device, such as an orthopedic implant 30, inserted, which in a non-limiting embodiment may be an elongated bone plate. With reference to FIGS. 2 and 3, a preferred embodiment of the encasement 11 may include a body 40, in this case a film, for the purpose of covering the implant on only one side. The embodiment shown has two fastening slots 45, 46 and four ends 41, 42, 43, 44. Ends 41, 42 may be open. Ends 43, 44 may be open or closed. In one embodiment, the fastening slots 45, 46 may be formed from a single encasement by folding an elastic sheet over itself and sealing along edges 451, 452 for slot 45 and edges 461, 462 for slot 46. In this embodiment, ends 43, 44 are folded edges that naturally close unless cut open. In an alternative embodiment, the fixation slots 45, 46 may be formed from at least two encasements that are grouped together to form a slot and sealed along edges 451, 452 for slot 45 and edges 461, 462 for slot 46. In this embodiment, ends 43, 44 may be left open without sealing or they may be closed with a seal. In yet a further alternative embodiment, the fixation slots 45, 46 may be formed from any one of the methods described above. In an embodiment, ends 41 and 42 are open ended through which an implant may be inserted into the fixation slots 45 and 46, respectively. In one embodiment, the length of the body 40 is shorter than the length of the corresponding implant, whereby the body 40 is stretched when an implant is inserted and achieves grip along the direction of the stretched length. In another embodiment, at least a portion of the circumference of fixation slot 45 and / or end 41 and / or end 43 and fixation slot 46 and / or end 42 and / or end 44 is smaller than the circumference of the corresponding implant, so that gripping is achieved by the elasticity of the encasement along the radial direction of the stretched circumference.In another embodiment, gripping can be achieved by a combination of a shorter body and smaller locking slots. It will be appreciated that both longitudinal and radial gripping effects can be combined in a single encasement embodiment. The type of embodiment provided by encasement 11 highlights the possibility that an encasement can be designed such that the drug is released from only one side of the implant to target the drug to the bone or nearby soft tissue as desired.

[0114] FIG. 4 illustrates a bioactive agent-loaded elastic encasement 12 disposed on a medical device such as an orthopedic implant 31, which in a non-limiting embodiment may be a hip implant, in accordance with the principles of the present invention. A preferred embodiment of the drug-retaining encasement 12 may include a body 50, in this case irregularly shaped, having two ends 51, 52. The ends 51, 52 may be open or closed. In one embodiment, both ends 51, 52 are open-ended, through which the implant may be inserted into the encasement 50, preferably from end 51 due to its irregular shape. In another embodiment, either one of the ends 51, 52 is closed-ended, such that the implant is inserted into the encasement 50 only from the open end, with the remaining edges being enveloped by 50. In these embodiments, at least a portion of the perimeter of the body 50 and / or ends 51 and / or ends 52 is smaller than the perimeter of the corresponding implant, such that the implant is held by a gripping force by at least a portion of the encasement. As previously mentioned, the gripping force generated by the elasticity of the one or more sheets used to form the implant can prevent the implant from slipping relative to the encasement (or vice versa) when the implant is implanted or secured in the patient's surgical site. In embodiments where the implant would have an irregular shape, the encasement 12 may be shaped to follow the contours of the implant to allow for a better fit to be achieved. The encasement 50 emphasizes that the elastic encasement can tightly grip the implant without creating extra space between the implant and the encasement. This is important for implants where space is limited and / or extra forces, such as shear forces, are exerted during implantation. Other encasements, punches, envelopes, encasements, etc., that cannot achieve a tight grip with a tight fit are not suitable for this class of implants.

[0115] FIG. 5 shows a bioactive agent-loaded elastic encasement 13 disposed on a medical device such as an orthopedic implant 32, which in a non-limiting embodiment may be an orthopedic screw or a dental implant screw, in accordance with the principles of the present invention. Encasements 13 (FIG. 5) and 10 (FIG. 1) are very similar in nature, with encasement 13 emphasizing the elastic encasement being able to retain the shape of the implant and thereby preserve the essential functionality of the implant. Other encasements, pouches, envelopes, encasements, etc. that cannot retain the shape of the implant are not suitable for this class of implants. A preferred embodiment of the encasement 13 for retaining the agent may include a body 60, in this case cylindrical, having two ends 61, 62. One of the ends 61, 62 is open and the other may be open or closed. In one embodiment, both ends 61 and 62 are open ends through which an implant may be inserted into the encasement 13 from either side. In another embodiment, end 61 is preferably closed ended such that the implant is inserted into encasement 13 only from the open end, with the remaining edges being gripped by 13. In an embodiment, at least a portion of body 60 and / or end 61 and / or end 62 is smaller than the corresponding circumference of the implant such that the implant is tightly gripped in the encasement, which prevents the implant / encasement from slipping relative to one another as the implant is being seated or afterwards.

[0116] In embodiments, the encasement 10, 11, 12, 13 may be formed from a single thin sheet or film 01 of bioabsorbable material, or multiple sheets. The film 01 in preferred embodiments is made of a biodegradable absorbable polymer (as defined above) and when implanted in vivo, dissolves over time and is absorbed by the patient, leaving only the implant if the implant is not made of an absorbable material. Alternatively, the implant may also be made of an absorbable material in other embodiments, in which case both the implant and the encasement will eventually dissolve. The film 01 may be generally thin and substantially planar in preferred embodiments, having a typical exemplary thickness T in the range of, but not limited to, about 0.01 μm to 1000 μm, more preferably about 0.04 mm to 0.2 mm. However, any suitable sheet thickness T may be used depending on the intended application, considerations of tear resistance when inserting the implant into the implant, drug administration period, etc. The film 01 may be made by any suitable means known in the art. As previously mentioned, it is specifically contemplated that one or more sheets of elastic material may be used, and these are also contemplated herein.

[0117] The encasements 10, 11, 12, 13 may be manufactured in one embodiment using sheets of degradable polymer that are heat treated and compression molded. In one embodiment, the drug or other biological agent may be dissolved or dispersed in the polymer while remaining in solution form. In one embodiment, the polymer solution is then processed into a film using conventional methods known in the art, perforated, and then formed into the encasements as described herein. Preferably, the film 01 may be perforated by any suitable technique, such as in one embodiment using a press, while the film is still in a generally flat state.

[0118] In one embodiment, the encasement 10, 12, 13 may be a seamless tubular structure. In another embodiment, the encasement 10, 12, 13 may be formed from a perforated film 01 by folding the film over itself to create a folded edge and sealing the opposing overlapping edge. In this case, one of the edges 201, 202; 501, 502; 601, 602 is a folded edge and the corresponding opposing edge is sealed to form a fused seam. In another embodiment, the encasement may be formed from at least two films 01 that are brought together and sealed along the edges 201, 202; 501, 502; 601, 602. It should be noted that any suitable technique may be used to seal and close the free ends, such as chemical welding or welding, the use of a biologically compatible adhesive, etc. Thus, the invention is not limited to the use of heat fusion techniques. Furthermore, the seal need not be a completely continuous seal.

[0119] In one embodiment of the elastic encasement, the absorbable polymer used in film 01 preferably comprises poly(lactide-co-caprolactone) (PLCL) (e.g., having a PLA:PCL ratio of 90:10 to 60:40) or its derivatives and copolymers thereof, and / or the bioabsorbable elastomeric polymeric material of one of the at least one polymeric layer is poly(DL-lactide-co-caprolactone) (DL-PLCL) (e.g., having a DL-PLA to PCL ratio of 90:10 to 50:50) or its derivatives and copolymers. and copolymers thereof, and / or the bioabsorbable elastomeric polymeric material of one of the at least one polymer layer can be poly(glycolide-co-caprolactone) (PGCL) (e.g., having a PGA to PCL ratio of 90:10 to 10:90) or derivatives and copolymers thereof, or, more particularly, the bioabsorbable elastomeric polymeric material of one of the at least one polymer layer can be a blend of PCL and PLA (e.g., a blend ratio of PCL and PLA having a weight:weight ratio of 1:9 to 9:1).

[0120] An encasement comprising at least a portion of a preferred absorbent, flexible polymer (e.g., PLCL) advantageously has good flexibility, elasticity and strength properties. In one embodiment, the elastic encasement can be easily stretched to conform to the size and shape of the implant, has sufficient strength to resist tearing during stretching of the encasement, and has sufficient gripping strength to resist movement of the encasement relative to the implant. In one preferred embodiment, the sheet 01 can preferably stretch to an extension of at least 100% of its initial unstretched length or width, and return to its original size or to a size less than or equal to the negative of the expanded size (90% of the difference between the expanded size and the original size). A single elastic encasement can advantageously conform to a wide range of implant sizes and / or shapes, and, as described herein, in preferred embodiments, preferably fits and grips the medical implant relatively snugly with or without minor modification by the surgeon. In one embodiment, the invention includes a kit that includes a limited number of encasements of different sizes and / or shapes that may be compatible across a large portion of the implant product line.

[0121] In a preferred embodiment, the encasement 10, 11, 12, 13 preferably further comprises a plurality of voids or perforations 100 of any suitable shape (substantially round, perforations or apertures, etc.) in one possible embodiment, thereby allowing the passage or transport of fluids through the encasement. The perforations 100 need not be perfectly circular, and in some embodiments may be oval or elliptical (not shown). The voids 100 are not limited to circular perforations. Preferably, the perforations 100 extend through the sheet 01 from the inner surface to the outer surface. The perforations 100 can advantageously provide for the distribution of drugs or biological agents to adjacent tissue and bone in an advantageous manner. In addition to being beneficial for the distribution of drugs, the perforations 100 can also increase the stretching ability of the encasement, improving ease of use and compatibility. Preferred exemplary non-limiting ranges of porosity based on the percentage of open area provided by perforations 100 relative to the total surface area of ​​film 01 are about 10% to about 90%, more preferably about 20% to about 80%. Perforations 100 preferably have a diameter of at least about 0.1 mm for satisfactory drug distribution and washout. In a preferred embodiment, perforations 100 have a diameter of at least about 1 mm. Diameters of about 0.1 mm or greater are generally considered in the art to represent macroporosity.

[0122] The encasements 10, 11, 12, 13 are preferably supplied separately in their own sterile pouches. The surgeon can use the encasement by removing it from the pouch and then sliding and stretching the encasement over the implant 30, 31 or 32 (30, 31 or 32). The implant can be slid into the encasement for a snug fit and to avoid excess unsupported encasement material at the ends. The encasements 10, 12, 13 can be trimmed with surgical scissors to match the length of the excess encasement to the length of the implant. Although a snug fit between the encasement and the implant may be desirable, a tight fit is not always necessary. The surgeon can use techniques similar to those described above to modify the encasements 10, 11, 12, 13 to custom fit the encasement to the particular size and shape of the implant that needs to be encased. The implant encased within the encasement is then implanted in the patient and secured in place using standard methods. It would be advantageous for surgeons to be able to deploy drugs from a variety of implants via encasement, and medical device companies would avoid the logistical hassle of developing and maintaining large inventories of uncoated implants and large inventories of coated implants that contain one or more drugs depending on the patient or indication being treated.

[0123] It will be appreciated that many different shapes and types of medical implants can be used with the present invention without limitation. Thus, the encasements 10, 11, 12, 13 can be used with devices other than the illustrated bone plate hip implants and screws, such as, but not limited to, non-orthopedic implants (e.g., stents, pacemakers, dental implants, bone grafts, etc.) and other orthopedic implants (e.g., tibial nails, femoral nails, spinal implants, etc.). Thus, in some embodiments, the surgeon can combine two or more encasements of the same or different sizes and shapes for an implant. For example, two or more encasements 10 can be combined without limitation for use with bone plates or other types of medical implants having L-shaped, T-shaped, X-shaped, H-shaped or other types and shapes of implants. It should be appreciated that the implant does not need to be completely encased by the encasement in all cases to effectively deliver drugs or other biological agents to the surrounding tissue.

[0124] While the detailed description and drawings represent preferred embodiments of the present invention, it will be understood that various additions, modifications and substitutions may be made therein without departing from the true spirit and scope of the present invention as defined in the appended claims. In particular, as will be apparent to those skilled in the art, the present invention may be embodied in other specific forms, structures, arrangements, proportions, sizes, and with other elements, materials, and components without departing from the true spirit or essential characteristics thereof. Those skilled in the art will appreciate that the present invention may be used with many modifications of the structures, arrangements, proportions, sizes, materials, and components used in the implementation of the present invention, which are specifically adapted to specific needs and operational requirements without departing from the principles of the present invention. Therefore, the presently disclosed embodiments are to be considered in all respects as illustrative and not restrictive, the scope of the present invention being defined by the appended claims and not limited to the foregoing description or embodiments. EXAMPLES

[0125] Film Elasticity Film samples made from poly(lactide-co-caprolactone) in the ratio range of 90:10 to 60:40 (lactide:caprolactone) were subjected to tensile testing. Figure 6 shows a graph of load versus elongation for a representative example of the film tested. The initial film length was 30 mm and the test shows pulling to at least 100% elongation (i.e., stretching to 200% of its original length). Figure 6 shows the corresponding force generated by the material on the force gauge at each elongation and its recovery path due to the elasticity of the material. Figure 6 also shows the ability of the material to stretch beyond 100% elongation without breaking and recover to near its original length at the end of the experiment. The experiment was performed using a tensile tester CMT-6001.

[0126] Drug Release from Films The following examples are intended to demonstrate the various layered films that may be used in the present invention and are not intended to be limiting in nature. These films may be used to create an encasement for any medical implant that requires one.

[0127] To illustrate the kinetics of drug release, film samples were cut into a size of 2 cm × 2 cm, which were immersed in vials containing 4 mL of PBS buffer (as the dissolution medium) for continuous drug dissolution testing. The vials were placed in an incubator shaker at 37 °C. Periodically, the dissolution medium was removed for reverse-phase HPLC analysis to determine the amount of rifampicin and minocycline (or vancomycin alone) dissolved, and replaced with fresh PBS solution (4 mL). The cumulative drug release was calculated and plotted (see Figures 8-9).

[0128] Table 1 and Figure 7 list a series of designs used in the examples. The table lists a number of polymers (either alone or in combination) and antibiotics that can be used to generate compositions according to the present invention. It will be understood that other polymers and antibiotics may be used.

[0129] Table 1: Film matrix containing rifampin (R) and minocycline (M) [Table 1] EXAMPLES

[0130] (Design 7-1, Film Codes 1-1 and 1-2) For the avoidance of doubt, "Design 7-1" refers to the design shown in Figure 7-1. Any other references to "Design" should be construed accordingly.

[0131] 2-A Film casting of drug-absorbent films 1.8 g of PLCL resin, 700 mg of sorbitol and 160 mg of minocycline (film code 1-1; rifampicin for film code 1-2) were dissolved in 10 mL of acetone / ethanol solvent mixture with a ratio of 5:5 v / v. Mixed uniformly for more than 4 hours. After mixing, the solution became homogenous, then 5 mL of the solution was poured onto a glass plate and then sucked with a film applicator to form a film upon drying. After the film was completely dry, the solvent was evaporated and the film was removed from the glass plate.

[0132] 2-B Film casting of control layer film Similarly, 1.8 g of PLCL resin and 50 mg of sorbitol were dissolved in 10 mL of acetone. The homogeneous solution was poured onto a glass plate and drawn by a film applicator to form a film after evaporation of the solvent. The film was then removed from the glass plate.

[0133] 2-C Film Compression A composition according to Design 7-1 was prepared using two films according to 2-B sandwiching a film according to 2-A. The resulting stack of films was aligned and compressed in a hot press at 60° C. and 6 MPa for 50 seconds. EXAMPLES

[0134] (Design 7-2, Film Codes 1-3 and 1-4) 3-A Film casting of biodegradable drug films 1.8 g of PLCL resin (2:8 weight ratio) and 160 mg of minocycline (film codes 1-3; rifampicin for film codes 1-4) were dissolved in 10 mL of acetone / ethanol solvent mixture in a 5:5 v / v ratio. The film casting procedure was the same as that described in Example 2-A.

[0135] 3-B Spray coating of drug-PLGA mixture Similarly, 180 mg of PLCL resin and 20 mg of minocycline (film codes 1-3; rifampicin for film codes 1-4) were dissolved in 10 mL of acetone / ethanol solvent mixture in a 5:5 v / v ratio. The mixture was spray coated onto the film prepared in 2-A using 2 mL of the prepared solution by repeatedly passing the spray nozzle over both sides of film 2-A with the same number of passes. EXAMPLES

[0136] (Design 7-3, Film Codes 1-5 and 1-6) The middle three layers were prepared according to the procedure of Example 3. The two outer layers were prepared according to Example 2-B. The five-layer film stack was properly aligned and compressed by a hot press at 60° C. and 6 MPa for 50 seconds. EXAMPLES

[0137] (Design 7-4, Film Codes 1-7 and 1-8) The two outer layers were prepared according to Example 2-B. The two middle drug-polymer layers were prepared according to Example 3-B. The resulting film was properly aligned and compressed by a hot press at 60° C. and 6 MPa for 50 seconds. EXAMPLES

[0138] (Design 7-5, Film Codes 1-9 and 1-10) The two layers were prepared according to Examples 2-A and 3-A. The film pressing procedure was the same as for 2-C. EXAMPLES

[0139] (Design 7-6, Film Codes 1-11 and 1-12) 7-A Film Compression of Elastic Biodegradable Polymer Films The PLCL resin was heat-compressed at 150°C and 60 MPa for 1 minute.

[0140] 7-B Spray coating of drug-PLGA mixture 180 mg of PLCL resin and 20 mg of minocycline (film codes 1-11; rifampicin for film codes 1-12) were dissolved in 10 mL of acetone / ethanol solvent mixture in a ratio of 5:5 v / v. The mixture was spray coated onto the film prepared in 7-A using 2 mL of the prepared solution by repeatedly passing the spray nozzle over both sides of film 7-A with an equal number of passes.

[0141] 7-C Film Casting for Blending Small Molecule Drug Films 1.8 g of PLCL resin, 250 mg of polysorbate and 160 mg of minocycline (film code 1-1; rifampicin for film code 1-2) were dissolved in 10 mL of acetone / ethanol solvent mixture with a ratio of 5:5 v / v. The mixture was mixed uniformly for more than 4 hours. After mixing, the solution became homogenous, and then 5 mL of the solution was poured onto a glass plate and stretched by a film applicator to form a film upon drying. After the film was completely dry, the film was removed from the glass plate after the solvent was evaporated.

[0142] 7-D Film Compression A composition according to design 7-6 was prepared using two films according to 7-C sandwiching a film according to 7-A coated with 7-B. The resulting laminate of films was aligned and compressed in a hot press at 60° C. and 6 MPa for 50 seconds. EXAMPLES

[0143] (Design 7-7, Film Codes 1-13 and 1-14) 8-A Film Casting for Blends of Small Molecules Controlled Films 1.8g of PLCL resin and 50mg of polysorbate were dissolved in 10mL of acetone / ethanol solvent mixture with a ratio of 5:5 v / v. The mixture was mixed uniformly for more than 4 hours. After mixing, the solution became homogenous, and then 5mL of the solution was poured onto a glass plate and stretched by a film applicator to form a film upon drying. After the film was completely dry, the film was removed from the glass plate after the solvent was evaporated.

[0144] 8-B Film Compression A composition according to design 7-7 was prepared using two films according to 8-A sandwiching a film 7-A coated with 7-B. The laminate was further sandwiched between two films according to 7-C. The resulting laminate of films was aligned and compressed in a hot press at 60° C. and 6 MPa for 50 seconds. EXAMPLES

[0145] (Single layer, contains release agent, film codes 1-15 and 1-16) The film preparation procedure is the same as in Example 2-A for preparing a single layer. EXAMPLES

[0146] (single layer, no release agent, film codes 1-17 and 1-18) 10-A Film casting of drug-absorbent films 0.5 g of PLCL resin and 160 mg of minocycline (film code 1-1; rifampicin for film code 1-2) were dissolved in 10 mL of acetone / ethanol solvent mixture with a ratio of 5:5 v / v. The mixture was mixed uniformly for more than 4 hours. After mixing, the solution became homogenous, and then 5 mL of the solution was poured onto a glass plate and stretched by a film applicator to form a film upon drying. After the film was completely dry, the film was removed from the glass plate after the solvent was evaporated. EXAMPLES

[0147] (Mixed Drugs) The film was prepared according to the protocol of Example 4. The middle layer was prepared with a drug mixture of minocycline 120 mg and rifampin 160 mg. The two interrupted layers were prepared by spray coating minocycline according to Example 3-B. The two outer layers were prepared according to Example 2-B. The five-layer film stack was properly aligned and compressed by a hot press at 6 MPa for 50 seconds. The cumulative release profiles of the two antibiotics are shown in Figure 9. EXAMPLES

[0148] Figure 8 shows the cumulative release of two antibiotics from different layered film designs and single films (film codes 1-1 to 1-18) prepared in Examples 2 to 10. The drug densities of both antibiotics ranged from 0.05 mg to 0.1 mg / cm. 2 As shown in Figure 8, for single drug films, the absence of a release agent results in a film with very slow release, while the presence of a release agent results in a faster initial release and a fast release profile. Since minocycline is more hydrophilic than rifampin, it is released much faster. For the layered film design, the release profiles and initial burst rates of rifampin and minocycline can be tailored and well controlled through different designs.

[0149] The results show that by knowing the release behavior of each drug in different designs, the release profile of the drug mixture can be tailored to provide the desired release profile. This can be clearly seen from Figure 9, which shows a significant improvement from the literature data, where rifampin always has a lower initial burst and slower release profile than its other hydrophilic counterpart (in this case minocycline). EXAMPLES

[0150] Figure 10 shows the cumulative release of the antibiotic vancomycin from a further layered film design (7-8). In this example, a first film layer is prepared according to the method of 7-A above, except that minocycline is replaced with vancomycin, and a film layer prepared according to 7-C above is placed on top of it. Finally, a layer prepared according to 2-B is placed on top of the vancomycin-containing layer, and the three layers are then compressed together using the method of 2-C above to form the product.

[0151] The products show very consistent release between replicates as shown in Figure 10. Release experiments were performed following the procedures described above in the section entitled "Drug Elution from Films." EXAMPLES

[0152] The zone of inhibition (ZOI) of the film was determined according to the Kirby-Bauer method. In this study, E. coli, Staphylococcus aureus, and Staphylococcus epidermidis are selected for demonstration testing. E. coli has the highest minimum inhibitory concentration (MIC) among other bacteria commonly found in humans. The MIC of E. coli is 20 times higher than S. aureus, S. epidermidis, MRSA, Staphylococcus capitis, etc.

[0153] E. coli was inoculated from a stock solution into lysogeny medium (LB medium) and incubated at 37 °C, then spread evenly across the agar plate with a disposable spreader. A film with a diameter of 15 mm was firmly pressed into the center of the agar plate and incubated at 37 °C. Every 24 h, a piece was transferred to another fresh agar plate using sterile forceps. The diameter of the ZOI was measured and recorded daily.

[0154] Table 2: ZOI of multilayer composite films containing minocycline and rifampicin. [Table 2]

Claims

1. 1. An encasement for a medical implant, comprising: at least one sheet of resilient material configured to form an encasement for at least a portion of a medical implant; The at least one sheet of elastic material comprises: a pair of outermost layers, each outermost layer comprising a biodegradable polymer and a first biologically active agent; a pair of intermediate layers disposed in association with the pair of outermost layers, each intermediate layer comprising a biodegradable polymer and a second bioactive material, the second bioactive material being different from the first bioactive material; an inner layer disposed and bonded between the pair of intermediate layers, the inner layer comprising a biodegradable polymer that is free of a biologically active agent; A series of thermocompressed layers including wherein at least one of the pair of outermost layers or the pair of intermediate layers further comprises polysorbate; the biodegradable polymer in at least one of the pair of outermost layers, the pair of middle layers, or the inner layer comprises poly(lactide-co-caprolactone) (PLCL); and a length of the encasement is shorter than a corresponding length of the medical implant, such that when the medical implant is inserted into the encasement, the encasement is longitudinally stretched, the longitudinal stretching providing the encasement with a gripping force against the medical implant to inhibit the medical implant from slipping relative to the encasement during implantation of the medical implant; the at least one sheet of elastic material has an elastic recovery of 80% to 100% after stretching; Encasement.

2. 10. The encasement of claim 1, wherein the first bioactive agent or the second bioactive agent comprises minocycline.

3. 3. The encasement of claim 1 or 2, wherein the first biologically active agent or the second biologically active agent comprises rifampin.

4. An encasement described in any one of claims 1 to 3, wherein the polysorbate includes polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.

5. The encasement described in claim 4, wherein the polysorbate is polysorbate 20.

6. The encasement of any one of claims 1 to 5, wherein the biodegradable polymer in each of the pair of outermost layers, the pair of intermediate layers, or the inner layer comprises PLCL.

7. 7. The encasement of any one of claims 1 to 6, wherein the outer periphery of the encasement is smaller than the corresponding outer periphery of the medical implant, such that when the medical implant is inserted, the encasement expands radially and provides a gripping force along the radial direction.

8. 8. An encasement according to any one of claims 1 to 7, wherein the encasement is selected from a pacemaker encasement, a stimulation / sensory implant encasement, a subcutaneous implant encasement, a monitoring implant encasement, a breast implant encasement, an intrauterine device encasement, an Eustachian tube encasement, or a tube encasement.

Images